Cargando…
Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer()()
Heparanase (HPSE) is the dominant mammalian endoglycosidase and important tumorigenic, angiogenic, and pro-metastatic molecule. Highest levels of HPSE activity have been consistently detected in cells possessing highest propensities to colonize the brain, emphasizing the therapeutic potential for ta...
Autores principales: | Zhang, Lixin, Ngo, Jason A., Wetzel, Michael D., Marchetti, Dario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309682/ https://www.ncbi.nlm.nih.gov/pubmed/25622903 http://dx.doi.org/10.1016/j.neo.2014.11.007 |
Ejemplares similares
-
Prognostic significance of heparanase expression in primary and metastatic breast carcinoma
por: Vornicova, Olga, et al.
Publicado: (2017) -
Lapatinib: the evidence for its therapeutic value in metastatic breast cancer
por: Thomson, Andrew
Publicado: (2005) -
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010) -
Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015) -
ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
por: Deblois, Geneviève, et al.
Publicado: (2016)